Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Neuroendocrine × Docetaxel × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thyroid Carcinoma, Anaplastic 2 Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Squamous Cell Carcinoma of Head and Neck 1 Salivary Gland Neoplasms 1 Prostatic Neoplasms 1 Neoplasms 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Esthesioneuroblastoma, Olfactory 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Neuroendocrine 1 Carcinoma, Medullary 1 Breast Neoplasms, Male 1 Breast Neoplasms 1 Adrenocortical Carcinoma 1 Adenocarcinoma, Follicular 1

Interventions

Cisplatin 11 Everolimus 10 Nivolumab 7 Etoposide 7 Temozolomide 5 Ipilimumab 5 Carboplatin 5 Bevacizumab 5 lutetium Lu 177 dotatate 4 atezolizumab 4 Irinotecan 4 Capecitabine 4 pembrolizumab 3 avelumab 3 Paclitaxel 3 Fluorouracil 3 surufatinib 2 sintilimab 2 gallium Ga 68 dotatate 2 dostarlimab 2 cabozantinib 2 belinostat 2 azaspirane 2 Topotecan 2 Positron Emission Tomography Computed Tomography 2 Magnetic Resonance Imaging 2 Immunoglobulin G 2 IFL protocol 2 Fluorodeoxyglucose F18 2 EC regimen 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03837977 2024-12-30

NET02

The Christie NHS Foundation Trust

Phase 2 Completed

Neoplasms, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡